JTJie Tang

Jie Tang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jie Tang has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Chun Cheng

    Department of Pathogenic Biology, School of Medicine, Nantong University, Nantong, Jiangsu, 226001, People's Republic of China

    1 shared publication
  • Fen Guo

    Department of Oncology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China

    1 shared publication
  • Hong Liu

    Department of Hematology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226001, People's Republic of China

    1 shared publication
  • Lan-Lan Pan

    Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

    1 shared publication
  • Li Yao

    Department of Immunology, Medical College of Jiangnan University, Wuxi, Jiangsu, 214122, People's Republic of China

    1 shared publication
  • Ling Ma

    Department of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, PR China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, 211166, PR China

    1 shared publication

Latest Publications

  • Open Access

    Immuno-genomic-radiomics to predict response of biliary tract cancer to camrelizumab plus GEMOX in a single-arm phase II trial

    by Qiu-Ping Liu, Jie Tang, Yi-Zhang Chen, Fen Guo, Ling Ma, Lan-Lan Pan, Yi-Tong Tian, Xiao-Feng Wu, Yu-Dong Zhang, Xiao-Feng Chen


  • Open Access

    Elucidating the expression and function of Numbl during cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma (MM)

    by Yuejiao Huang, Xianting Huang, Chun Cheng, Xiaohong Xu, Hong Liu, Xiaojing Yang, Li Yao, Zongmei Ding, Jie Tang, Song He, et al.

    Background: Cell adhesion-mediated drug resistance (CAM-DR) is a major clinical problem that prevents successful treatment of multiple myeloma (MM). In particular, the expression levels of integrin β1 and its sub-cellular distribution (internalization and trafficking) are strongly associated with CAM-DR development.Methods: Development of an adhesion model of established MM cell lines and detection of Numbl and Integrinβ1 expression by Western Blot analysis. The interaction between Numbl and Integrinβ1 was assessed by a co-immunoprecipitation (CO-IP) method. Calcein AM assay was performed to investigate the levels of cell adhesion. Finally, the extent of CAM-DR in myeloma cells was measured using cell viability assay and flow cytometry analysis.Results: Our preliminary date suggest that Numbl is differentially expressed in a cell adhesion model of MM cell lines. In addition to binding to the phosphotyrosine-binding (PTB) domain, the carboxyl terminal of Numbl can also interact with integrin β1 to regulate the cell cycle by activating the pro-survival PI3K/AKT signaling pathway. This study intends to verify and elucidate the interaction between Numbl and integrin β1 and its functional outcome on CAM-DR. We have designed and developed a CAM-DR model using MM cells coated with either fibronectin or bone marrow stromal cells. We assessed whether Numbl influences cell-cycle progression and whether it, in turn, contributes to activation of PI3K/AKT signal pathway through the adjustment of its carboxyl end. Finally, we showed that the interaction of Numbl with integrin β1 promotes the formation of CAM-DR in MM cells.Conclusions: Our findings elucidated the specific molecular mechanisms of CAM-DR induction and confirmed that Numbl is crucial for the development of CAM-DR in MM cells.